Skip navigation

Life Science Leadership Series: Strategies and Funding of Clinical Trials

08:30 - 18:30

The Nucleus, Chesterford Research Park, Little Chesterford CB10 1XL
24 September 2015

Supported by 


The affordability of innovative new medicines is an increasingly debated topic within the Healthcare and Pharmaceutical industries. The rise of regulatory hurdles, population demographics and potential fragmentation of markets are challenging the systems of all healthcare providers and payers. They combine to create a huge incentive to render drug development more efficiently in order to reduce the cost of goods. 

The Leadership Series will be a mix of keynote presentations, panel discussion and case studies. It will explore the challenges of efficient drug development funding by addressing evolving healthcare needs and affordability and providing concrete insights regarding data packaging, licensing and selecting development partners.


10.00 - Registration opens

10.30 - Welcome and introduction
Tony Jones, Director of Business Development, One Nucleus

10.40 – Keynote Presentation 1: Does innovative have to mean expensive when it comes to new medicines?
Tim Gamble
, SCRIP Intelligence

11.10 – Keynote Presentation 2: Clinical Development Challenges – A global consideration
Marieme Ba
, London School of Clinical Research

11.40 – Plenary Panel: How can we make future healthcare affordable?

Chair: Professor Tom Macdonald, Professor of Immunology and formerly Dean of Research Barts and the London School of Medicine and Dentistry, Queen Mary University of London 

Ellen Thomas, Genomics England
Oliver Rausch, NOCRI
Nick Clarke, Pfizer

Sandy Johnston, Price Waterhouse Coopers
Emma Gray, MS Society 

12.40 - Closing remarks 

12.45 - Lunch and networking 

14.05 - Introduction to afternoon session

Chair: Greer Deal, GRS

14.10 – Ensuring a solid foundation: Early scientific and pre-clinical data packages

Mehryar Behizad

, Pirus Consulting Ltd
*Click here to view the presentation*

14.30 – Funding from lead molecule to phase II: How many pitfalls?  

Keith Powell, Canbex

14.50 – Patient engagement in clinical trials design

Vincenzo Garzya, AstraZeneca

15.10 - Tea, coffee and networking

15.40 – Early Access to Medicine Scheme

Daniel O’Connor, MHRA
*Click here to view the presentation*
Steve Bates

16.10 – Case study 1 – Clinical Development without precedent, Lessons from a Novel Drug in a Rare Condition
Lachlan Hay
, Clinuvel

16.40 – Case study 2 – Preclinical to Clinical translation of challenge models
Nick Clarke, Senior Director and Project Leader, Pfizer

17.10 – Closing Remarks

17.15 - Drinks Reception

18.15 – Close

Gold members: £75 + VAT
Silver member: £175 + VAT
Non-members: £275 + VAT
Academics: £75 + VAT (contact for your code)

Title: Life Science Leadership Series: Strategies and Funding of Clinical Trials
Start: 2015-09-24 08:30:00Z
End: 2015-09-24 18:30:00Z